Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 15/20 | 0.74 |
| ▸ | RARA | P10276 | 1/20 | 0.74 |
| ▸ | RARB | P10826 | 1/20 | 0.74 |
| ▸ | RARG | P13631 | 1/20 | 0.74 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9071431 | 0.86 | MAPT (0.60) | GCKRARARARBRARGNR1H4 | |
| SCHEMBL31456329 | 0.85 | GCK (1.00) | GCKRARARARBRARG | |
| SCHEMBL1794696 | 0.85 | GCK (1.00) | GCKRARARARBRARG | |
| SCHEMBL2664524 | 0.84 | MAPT (0.73) | GCKRARARARBRARGNR1H4 | |
| SCHEMBL2664877 | 0.79 | GCK (0.74) | GCKRARARARBRARGNPC1 | |
| SCHEMBL14505779 | 0.78 | GCK (0.89) | GCKRARARARBRARG | |
| SCHEMBL13703970 | 0.78 | GCK (0.70) | GCKRARARARBRARGNPC1 | |
| SCHEMBL1793720 | 0.78 | GCK (0.82) | GCKRARARARBRARG | |
| SCHEMBL2664722 | 0.78 | GCK (0.63) | GCKRARARARBRARGNR1H4 | |
| SCHEMBL4276418 | 0.77 | PLA2G2A (0.54) | GCKRARARARBRARGNR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7524957-B2 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2009-04-28 | — | — | US | disclosed |
| US-7524957-B2 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2009-04-28 | — | — | US | disclosed |
| US-20080207636-A1 | Compounds Effecting Glucokinase | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| US-20080207636-A1 | Compounds Effecting Glucokinase | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207636-A1 | Compounds Effecting Glucokinase | GCKR, GCK, SLC5A2 | GCK 2/4885RARA 3925/4885RARB 3902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.